Mumbai’s medical community is observing a significant rise in lower respiratory infections among children, leading to increased hospital admissions. This surge highlights the urgent need for effective RSV prevention India strategies. Respiratory Syncytial Virus (RSV) is primarily responsible for many of these cases, and it is a highly contagious pathogen. Dr. Indu Khosla, a paediatric pulmonologist, noted a high number of children with RSV-related infections in paediatric intensive care units across city hospitals. For example, SRCC Children’s Hospital and Somaiya Hospital are both managing numerous young patients severely affected by RSV.
Understanding RSV Infection in Indian Children
Globally, acute lower respiratory infections (ALRI) are a leading cause of illness and death in children under five. Human respiratory syncytial virus is often the most common viral cause. In 2019, approximately 33 million ALRI cases occurred worldwide, resulting in over 3 million hospitalisations and an estimated 26,300 in-hospital deaths for children younger than five years. Two out of three infants typically contract RSV during their first year, and nearly all children are infected by their second birthday. While RSV occurs year-round, cases often spike during monsoon seasons in India. Children under two years are most susceptible to severe infections; however, adults can also experience RSV-related complications.
Advances in RSV Prevention India: Introducing Nirsevimab
The introduction of nirsevimab marks a significant development in RSV prevention India. This product, from Sanofi Healthcare India Private Limited, is being promoted and distributed by Dr. Reddy’s. Importantly, nirsevimab is not a traditional vaccine. Instead, it functions as a long-acting monoclonal antibody. Dr. Khosla explained that this antibody prevents the virus from binding to cells. Administered as an intramuscular injection, it offers protection against RSV infections for up to one year, effectively acting like a vaccine. This innovative approach provides crucial defense for vulnerable populations. For those interested in understanding the broader scope of pediatric care and infectious diseases, consider exploring our International Post Graduate Program In Pediatrics.
Who Benefits from Nirsevimab?
Nirsevimab is specifically advised for high-risk infants, especially those born prematurely. A second dose is also recommended for such children in their second year of life. However, this drug, recently launched in India, carries a substantial cost, approximately Rs 40,000 per shot. This price point could potentially deter many parents, particularly young families still establishing their careers, from accessing the medication. Despite this, Dr. Khosla observed that some parents, especially those with particularly vulnerable children, are willing to bear the expense to ensure their child’s protection. She mentioned having a shot scheduled for early next week, underscoring the demand among informed parents. Learning about specific interventions and preventative measures for children is crucial, and our Certification Course In Healthy Child offers valuable insights.
Frequently Asked Questions
Q1: What is RSV and why is it a concern for children in India?
RSV, or Respiratory Syncytial Virus, is a highly contagious virus causing lower respiratory infections, especially in young children. It is a major cause of hospitalizations and severe illness among infants and children under five, with a notable increase during the monsoon season in India.
Q2: How does nirsevimab work for RSV prevention?
Nirsevimab is a long-acting monoclonal antibody, not a vaccine. It prevents the the RSV virus from attaching to cells, offering protection against infection for up to a year with a single intramuscular injection. It functions similarly to a vaccine by providing passive immunity.
Q3: Who is recommended to receive nirsevimab in India?
Nirsevimab is recommended for high-risk infants, particularly those born prematurely. A second dose is also advised for these children during their second year. Its high cost, however, presents a significant barrier for many families.
References
- Lower respiratory infection on the rise among Mum kids – ETHealthworld
- Disease Burden Due to Respiratory Syncytial Virus in Indian Pediatric Population: A Literature Review – PMC – PubMed Central
- Prevalence of respiratory syncytial virus infection among children hospitalized with acute lower respiratory tract infections in Southern India – PubMed Central
- India Approves Nirsevimab to Prevent RSV Infection in Infants – Docplexus
- Sanofi gets drug regulator nod to market RSV therapy in India – The Economic Times
- Dr Reddy’s expands partnership with Sanofi to launch Beyfortus for RSV prevention in India
- There’s Urgent Need For RSV Immunisation In India As Virus Continuous To Claim Infant Lives, Says Top Pediatrician | Health and Me
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.